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Abstract
Background: We have previously shown that NK (CD56
+CD3
-) and NKT-like (CD56
+CD3
+) cells are reduced in both
numbers and cytotoxicity in peripheral blood. The aim of the present study was to investigate their numbers and
function within induced sputum.
Methods: Induced sputum cell numbers and intracellular granzyme B and perforin were analysed by flow
cytometry. Immunomagnetically selected CD56
+ cells (NK and NKT-like cells) were used in an LDH release assay
to determine cytotoxicity.
Results: The proportion of NK cells and NKT-like cells in smokers with COPD (COPD subjects) was significantly
higher (12.7% and 3%, respectively) than in healthy smokers (smokers) (5.7%, p < 0.01; 1%, p < 0.001) and non-
smoking healthy subjects (HNS) (4.2%, p < 0.001; 0.8%, p < 0.01). The proportions of NK cells and NKT-like cells
expressing both perforin and granzyme B were also significantly higher in COPD subjects compared to smokers
and HNS. CD56
+ cells from COPD subjects were significantly more cytotoxic (1414 biological lytic activity) than
those from smokers (142.5; p < 0.01) and HNS (3.8; p < 0.001) and were inversely correlated to FEV1. (r = -0.75;
p = 0.0098).
Conclusion: We have shown an increased proportion of NK and NKT-like cells in the induced sputum of COPD
subjects and have demonstrated that these cells are significantly more cytotoxic in COPD subjects than smokers
and HNS.
Background
Chronic obstructive pulmonary disease (COPD) is a
complex condition consisting of emphysema, respiratory
bronchiolitis and chronic bronchitis [1]. It is projected
to be the fifth commonest cause of morbidity and the
third leading cause of death worldwide by 2030 [2].
Tobacco smoking is established as the main aetiological
factor for COPD and it is now accepted that COPD is
an inflammatory disorder.
Inflammation of the airways is present in COPD with
increased numbers of inflammatory cells from both the
innate and adaptive host response, such as macrophages
and lymphocytes in the airway wall [3] and neutrophils
in the airway lumen [4]. Many of these cells have the
potential to cause the damage seen in the airways of
patients with COPD, including three main hetero-
geneous and functionally distinct classes of human killer
cells; namely CD8
+ T lymphocytes, CD56
+CD3
- (natural
killer; NK) cells and CD56
+CD3
+ (NKT-like) cells [5].
Killer cells lyze their targetc e l l sb yt w om e c h a n i s m s :
membranolysis, in which secreted molecules, such as
perforin and granzymes, form pores in the membrane of
target cells [6]; and apoptosis, mediated through the
triggering of apoptosis-inducing (Fas-like) surface mole-
cules of the target cell [7].
Airway inflammation has been studied in bronchial
biopsy samples and bronchoalveolar lavage (BAL) fluid
[8]. Recently, it has been reported that soluble granzyme
B levels and the proportion of T cells expressing intra-
cellular granzyme B or perforin were increased in the
BAL of both current and ex-smokers smokers with
COPD [9]. Others have shown a decrease in NK cell
numbers in the BAL of patients with chronic bronchitis
[10], but to date, no in-depth study of BAL NKT-like
cells in patients with COPD has been performed.
Studies in sputum have demonstrated increased perforin
expression and cytotoxic activity of CD8
+ lymphocytes
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other types of killer cells (namely NK and NKT-like cells)
as these can also express CD8 on the cell surface. Informa-
tion on the functional phenotypes of NK and NKT-like
cells in induced sputum in COPD is limited.
We have previously shown that there are significant
differences in the proportions, subsets, intracellular pro-
teins and cytotoxic activities of NK cells and NKT-like
cells in the peripheral blood of COPD subjects. Specifi-
cally, peripheral cell numbers and cytotoxicity of these
cells were reduced in COPD [12]. However a study of
peripheral cells does not necessarily reflect changes in
the airway. The first step of assessing the potential
importance of these cells in the inflammatory process
would be to assess their numbers and function within
the airways. Therefore, in this study we have extended
the findings of our previous study to investigate, within
induced sputum, the number and cytotoxic function
of the three main classes of human killer cells; CD8
+
T lymphocytes, NK cells and NKT-like cells.
Methods
Study population and procedures
The Nottingham Local Research Ethics Committee
approved the study protocol and written informed con-
sent was obtained from the 26 subjects before entering
the blinded study. Of these, the 11 participants diag-
nosed as having COPD (COPD subjects), according to
the ATS guidelines, were current or ex-smokers who
had accrued at least a 20 pack year smoking history and
had an FEV1 below 80% of predicted with an FEV1/FVC
ratio of <70% and reversibility to an inhaled beta-2 ago-
nist of <10% or <200 mls absolute improvement. Ten
healthy smokers (smokers), defined as smokers without
airflow limitation, and five healthy non-smokers (HNS),
with an FEV1 above 80% of predicted, were recruited
and matched for age and for the healthy smokers, smok-
ing history, as closely as possible. Table 1 details the
demographic and spirometric data of the subjects. Parti-
cipants were excluded if they had a history of tuberculo-
sis (TB), a clinical suspicion of current infection, history
of physician diagnosed asthma or a positive skin prick
test response to grass pollen, house dust mite, cat dan-
der and dog hair (ALK-Abelló). COPD subjects were
also excluded if they had had an exacerbation within the
previous 6 weeks, were a1-anti-trypsin deficient or had
other lung disease.
Sputum induction
Sputum was induced by inhalation of hypertonic saline
as described previously [13] with the difference that the
subject was given salbutamol (400 mg) via a volumatic,
rather than 1 mg terbutaline. The sample was placed on
ice and processed within 1 hour.
Cell isolation and fractionation
The sputum was concentrated in a petri dish on ice, weight
was calculated and 0.1% dithiothreitol (DTT) was added at
a 4× weight/volume ratio. Sputum was dispersed, vortexed
and then placed on a roller mixer. An equal volume of
PBS was then added, vortexed and filtered through 48 μm
nylon gauze. An aliquot for cell counting to assess viability
and squamous cell contamination was taken. The remain-
ing sample was centrifuged and resuspended.
CD56
+ cells were isolated using a-CD56 microbeads
(Miltenyi Biotech Ltd) according to manufacturers’
instructions. Briefly, cells were incubated for 15 minutes
at 4°C with a-CD56 microbeads and separated on a
refrigerated MS column using cold PBS containing 1%
FCS and 0.4% EDTA. The resulting positive fraction was
washed and resuspended in RPMI 1640 medium. Fol-
lowing isolation, all fractions were washed, counted and
purity confirmed at ≥90% by flow cytometric analysis.
Flow cytometric analysis
Cells were washed with PBA, fixed in 3% formaldehyde in
isotonic azide free solution and given a final wash with
PBA - 0.04% saponin with 10% FCS. Labelled antibodies
(Table 2) were added at the recommended concentration
and the cells were incubated for two hours at 4°C in the
dark. Excess antibody was removed by washing and cells
were stored in 0.5% formaldehyde in isotonic azide free




Subjects 51 01 1
Age (years) 51 (42-68) 51 (44-68) 63 (44-73)
Gender (M/F) 1/4 5/5 6/5







FEV1 (% pred) 112 (88-124) 100 (89-122) 59 (37-73)
FEV1/FVC (%) 78 (72-86) 74 (73-82) 54 (39-69)
ΔFEV1 post bronch 2.2 (1.1-3.5) 1.6 (1.1-2.7) 3.9 (3.6-4.3)
BMI (kg/m






N/A N/A 3 (2-4)
Distance walked in
6 min (m)
N/A N/A 291 (168-554)
BODE Index N/A N/A 5 (1-7)
Results are expressed as median with range in brackets.
HNS, non-smoking healthy subjects; COPD, chronic obstructive pulmonary
disease; FEV1, forced expiratory volume in 1 second; pred, predicted value;
FVC, forced vital capacity; GCS, Glucocorticosteroids.
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labelled cells was performed using an EPICS Altra (Beck-
man Coulter). Fifty thousand live-gated events were col-
lected for each sample and isotype matched antibodies
were used to determine binding specificity. Data were ana-
lysed using WEASEL version 2.3 (WEHI). Necrotic cells
were excluded from analysis according to their forward
and side scatter characteristics.
Cytotoxicity assay
A commercially available lactate dehydrogenase (LDH)
kit (CytoTox 96 Non-Radioactive Cytotoxicity Assay,
Promega) was used with erythroleukaemic K562 cells
(ECACC) as the target cell line. Briefly, the effector and
target cells were mixed at a ratio of 5:1, plated in quadru-
plicate on a 96-well U-bottomed plate and incubated for
4 h at 37°C in a humidified atmosphere containing 5%
CO2. After incubation, the plate was centrifuged, the
supernatants collected and incubated for 30 min at room
temperature with the Substrate Mix provided with the kit
to detect LDH activity. A stop solution was added and
the absorbance of the sample was measured at 490 nm
on an Emax precision microplate reader (Molecular
Devices) using SOFTmax software (Molecular Devices).
The amount of cell-mediated cytotoxicity was calculated
by subtracting the spontaneous LDH released from the
target and effector cells from the LDH released by lysed
target cells, using the following equation:
Specific lysis (%) = {(effector/target cell mix - sponta-
neous effector LDH release - spontaneous target LDH
release)/(maximum target LDH release - spontaneous
target LDH release)}x100
The biological lytic ability was then calculated by mul-
tiplying the lytic activity per cell by the total number of
CD56
+ cells per gram of induced sputum.
Statistical analysis
The statistical analysis was performed with Prism soft-
ware, version 4.0c (GraphPad). Normality was detected
using the Kolmogorov-Smirnov test. As some data were
non-normally distributed all are expressed as median
(range), unless otherwise stated. Differences between the
three groups of subjects were tested using the non-
parametric Kruskal-Wallis test with post hoc pairwise
comparisons made by the Dunn’s Multiple Comparison
test to determine which pair was statistically signifi-
cantly different. P values of less than 0.05 were consid-
ered to indicate statistical significance.
Results
There was no statistical difference between groups in
terms of age (Kruskal-Wallis test). Furthermore, there
was no significant difference in smoking history between
COPD subjects and healthy smokers.
Comparison of constituent cells in induced sputum
The viability of the cells (% total) in induced sputum did
not differ between COPD subjects, smokers and HNS
(median, range): 83 (75-94), 82 (72-93) and 86 (75-94),
respectively. In all samples, more than 90% of the cells
Table 2 Antibodies used for flow cytometry
Antigen Fluorochrome Isotype Clone Source
CD3 ECD
PC7
Mouse IgG1 UCHT1 Beckman Coulter, Luton, UK
CD4 FITC
PC5
Mouse IgG1 13B8.2 Beckman Coulter, Luton, UK
CD8 PC5
APC
Mouse IgG1 B9.11 Beckman Coulter, Luton, UK
CD8 ECD Mouse IgG1 SFCl21Thy2D3 Beckman Coulter, Luton, UK
CD16 PC7 Mouse IgG1 3G8 Beckman Coulter, Luton, UK
CD19 PC5 Mouse IgG1, k J4.119 Beckman Coulter, Luton, UK
CD45RA FITC
PE
Mouse IgG1 ALB11 Beckman Coulter, Luton, UK




Mouse IgG1 N901 Beckman Coulter, Luton, UK
CD62L PC5 Mouse IgG1 DREG56 Beckman Coulter, Luton, UK
Granzyme B FITC Mouse IgG1k GB11 Becton Dickinson, Oxford, UK
Perforin PE Mouse IgG2b (G9 Becton Dickinson, Oxford, UK
CXCR3 PE Mouse IgG1, k 1C6/CXCR3 Becton Dickinson, Oxford, UK
VLA-4 FITC Mouse IgG1 HP2/1 Beckman Coulter, Luton, UK
ECD, phycoerythrin-Texas Red-x; FITC, fluorescein isothiocyanate; PC5, phycoerythrin-cyanin 5.1; PC7, phycoerythrin-cyanin 7; PE, phycoerythrin
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g
-1) was significantly higher in COPD subjects than in
smokers and HNS (Table 3). The TCC was also higher
in smokers than in HNS (Table 3). The differences in
cellular parameters amongst the three groups are pre-
sented in Table 3. The proportions of neutrophils and
lymphocytes were higher in COPD subjects than in the
other two groups, with the proportion of macrophages
lower.
Flow cytometric analysis of the lymphocytes showed
that the proportions of CD8
+ T lymphocytes, NK
(CD56
+CD3
-) cells and NKT-like (CD56
+CD3
+) cells
were significantly higher in COPD subjects compared to
t h eo t h e rt w og r o u p s( F i g u r e1 ) .H o w e v e r ,t h eC D 4
+/
CD8
+ ratio was significantly lower in COPD subjects
(0.70) compared to smokers (1.4; p < 0.001) and HNS
(1.0; p < 0.001). There was also a significant increase in
the proportion of B lymphocytes in COPD patients
compared to smokers and HNS (Figure 1).
Further analysis of the CD8
+ T lymphocytes by flow
cytometry revealed that COPD subjects had an increased
proportion of memory cells (CD45RO
+RA
-)a n da
reduction in the proportion of naïve cells (CD45RO
-RA
+) compared to the other two groups (Figure 2A). The
proportion of TEMRA cells (CD45RO
+RA
+)w a sa l s o
higher in COPD subjects.
The subpopulation split of NK cells showed a higher
proportion of immunoregulatory CD56
brightCD16
- NK
cells in COPD subjects, compared to the other two
groups (Figure 2B ). There was no measurable difference
in the proportion of NK cells expressing CD8 in any of
the three groups (data not shown).
NKT-like (CD56
+CD3
+) cells in COPD subjects
showed an increased proportion expressing CD8 and a
decreased proportion expressing CD4 (Figure 2C),
compared to the other two groups. There was no dif-
ference between groups for the double negative
fraction.
Table 3 Cellular populations in sputum of HNS, smokers and COPD subjects (median, range)
HNS
(group A, n = 5)
Smokers
(group B, n = 10)
COPD Subjects
(group C, n = 11)
p values
TCC, × 10
7 cells/g 1.24 (0.4-1.9) 4.93 (2-7.4) 10.66 (5.2-14.9) COPD vs Smokers p < 0.05
COPD vs HNS p < 0.001
Neutrophils, × 10
7 cells/g 0.53 (0.14-0.63) 2.37 (1.23-4.06) 7.94 (3.82-12.13) COPD vs Smokers p < 0.01
COPD vs HNS p < 0.001
Macrophages, × 10
7 cells/g 0.58 (0.21-0.95) 2.41 (0.88-3.99)) 1.89 (0.76-2.75) COPD vs HNS p < 0.05
Smokers vs HNS p < 0.01
Lymphocytes, × 10
7 cells/g 0.01 (0.00-0.02) 0.16 (0.04-0.51) 0.90 (0.28-1.44) COPD vs Smokers p < 0.05
COPD vs HNS p < 0.001
Eosinophils, × 10
7 cells/g 0.009 (0.001-0.023) 0.022 (0.002-0.056) 0.122 (0.019-0.203) NS
Neutrophils, % 35.3 (29.8-41.9) 55.5 (38.1-67.2) 74.2 (59.4-82.7) COPD vs Smokers p < 0.01
COPD vs HNS p < 0.001
Macrophages, % 51.4 (40.9-63.6) 42.8 (35.5-62.4) 19.6 (6.8-27.2) COPD vs Smokers p < 0.001
COPD vs HNS p < 0.01
Lymphocytes, % 0.9 (0.3-1.3) 3.9 (0.7-7.4) 9.5 (3.2-13.5) COPD vs Smokers p < 0.05
COPD vs HNS p < 0.001
Eosinophils, % 0.7 (0-1.2) 0.6 (0.1-0.9) 1.3 (0.2-1.9) NS
Results are expressed as median of total non-squamous cells with range in brackets
Figure 1 Proportion and type of lymphocytes from the
induced sputum of HNS (n = 5), smokers (n = 10) and COPD
subjects (n = 11). Results show a significant increase in the
proportion of all three cytotoxic cells (CD8
+, NK and NKT-like cells)
in COPD subjects compared to HNS and smokers. Cell types were
determined by flow cytometric analysis of monoclonal antibodies.
CD19, B cells; CD4, T helper cells; CD8, cytotoxic killer cells; CD56
+CD3
-, NK cells; CD56
+CD3
+, NKT-like cells. **: p < 0.01, ***: p <
0.001.
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The expression of perforin and granzyme B were studied
in CD8









The proportion of CD8
+ T lymphocytes expressing
both perforin and granzyme B was significantly higher
in COPD subjects (43.9) compared to HNS (18.6; p <





- NK cells expres-
sing both perforin and granzyme B were also signifi-
cantly higher in COPD subjects (74.6 and 44.8,
respectively) compared to both HNS (46.2; p < 0.001
and 18.5; p < 0.01) and smokers (55.9; p < 0.01 and
24.9; p < 0.05)(Figure 3B). The proportion NKT-like
(CD56
+CD3
+) cells expressing both perforin and gran-
zyme B were also significantly higher in COPD subjects
(63.8) compared to both HNS (14.5; p < 0.001) and
smokers (43.4; p < 0.01)(Figure 3B).
The proportion of CD8
+ T lymphocytes that expressed
only perforin and no granzyme B was significantly
higher in both smokers (8.0; p < 0.01) and COPD sub-
jects (4.6; p < 0.05) than in HNS (1.4) (data not shown).
The proportion of NKT-like (CD56
+CD3
+) cells that
expressed only perforin and no granzyme B was signifi-
cantly higher in both smokers (14.0; p < 0.001) and
HNS (13.8; p < 0.01) than in COPD subjects (5.4) (data
not shown). There was no difference in the proportions
of CD56
dimCD16
+ NK cells and CD56
brightCD16
- NK
cells expressing only perforin and no granzyme B.
Examining the proportion of cells expressing only gran-
zyme B and no perforin revealed no differences between
groups and cell types (data not shown).
Cytotoxic activity of CD56
+ cells
To establish if the increased proportions of CD56
+ cells
that expressed both perforin and granzyme B were cyto-
toxic in the LDH release assay, CD56
+ cells were
Figure 2 Proportion of CD8+ T lymphocyte subsets (Panel A), NK (CD56
+CD3
-) subsets (Panel B) and NKT-like (CD56
+CD3
+)s u b s e t s
(Panel C) from the induced sputum of HNS (n = 5), smokers (n = 10) and COPD subjects (n = 11). Panel A shows the proportion of




-) was significantly increased in COPD subjects compared to HNS (*: p <
0.05) and smokers (**: p < 0.01). Panel B shows the proportion of CD56
brightCD16
- NK cells was significantly increased in COPD subjects
compared to HNS (*: p < 0.05) and smokers (***: p < 0.001). Panel C shows significantly more CD8
+CD56
+CD3
+ cells in the induced sputum of
COPD subjects compared to HNS (**: p < 0.01) and smokers (***: p < 0.001).
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samples were ≥ 90% pure with respect to B lymphocytes,
helper T lymphocytes, CD8
+ T lymphocytes, neutrophils
and monocytes (Table 4).
Using the same number of effector cells (effector to
target ratio of 5:1) the CD56
+ cells from COPD subjects
were significantly more cytotoxic (36.8% specific lysis)
than those from smokers (22.4%; p < 0.01) and HNS
(16.1%; p < 0.001) (Figure 4A). When taking into
account for the differences in cell numbers on overall
cytotoxicity, by examining the product of CD56 cell
numbers and lytic activity of the CD56
+ cells from
COPD subjects (which we have termed biological lytic
activity) the significant differences remain (Figure 4B)
and this inversely correlated with lung function, as
assessed by FEV1 measurement (r = -0.75; p = 0.0098)
(Figure 4C).
Adhesion molecule expression
To examine a possible mechanism of selected cell recruit-
ment to the lung the adhesion molecules CXCR3 and
VLA-4 were measured. The proportion of CD8+ T lym-
phocytes, CD56
dimCD16
+ NK cells, CD56
brightCD16
- NK
cells and NKT-like cells expressing CXCR3 was
significantly higher in COPD subjects than in smokers
(Figure 5A). The proportions of these cells expressing
VLA-4 were also significantly higher in COPD subjects
than in smokers (Figure 5B).
Discussion
Here we report for the first time that NK cells
(CD56
+CD3
-) and NKT-like cells (CD56
+CD3
+)f r o m
the induced sputum of COPD subjects are increased in
both number and proportion and have a higher cyto-
toxic ability compared to HNS and smokers.
I nt h i ss t u d yw eh a v ea l s oc o n f i r m e dt h ef i n d i n g so f
others, namely predominant neutrophilia [14], the pre-
sence of significantly more lymphocytes in COPD sub-
jects, and a reduced CD4/CD8 ratio [15]. The increased
proportion of B lymphocytes in the induced sputum of
COPD subjects compared to smokers has not previously
been reported, although B cell follicles have been
demonstrated previously in both the small airways of
COPD subjects [16,17] and the lung parenchyma [18]
highlighting a potentially important role for these cells
in COPD.
The proportion of highly cytotoxic TEMRA cells
within the CD8
+ fraction was significantly increased in
COPD subjects compared to smokers and HNS. This
increased proportion of TEMRA cells, which are deemed
highly cytotoxic due to their high perforin content
[19], has not been previously reported in induced spu-
tum and it is possible to hypothesise that these cells
are causing some of the damage seen in the COPD air-




+ fraction were also significantly
increased in COPD subjects with a corresponding
decrease in naïve cells (CD45RO
-RA
+). These memory
cells could accelerate the inflammatory response seen




+ NK cells, CD56
brightCD16
- NK cells and NKT-like (CD56
+CD3
+) cells from HNS (n = 5), smokers (n = 10)
and COPD subjects (n = 11). Double stained cells (Panel B) are deemed cytotoxic. *: p < 0.05, **: p < 0.01, ***: p < 0.001.
Table 4 Purity of immunomagnetically separated CD56
+
cells from the induced sputum of the studied groups
HNS Smokers COPD subjects
CD56
+ cells 91.7 (± 0.8) 94.3 (± 1.1) 94.8 (± 1.4)
B cells (CD19
+) 2.2 (± 0.4) 1.8 (± 0.8) 1.4 (± 0.7)
Helper T cells (CD4
+) 1.4 (± 0.5) 0.7 (± 0.1) 0.6 (± 0.5)
Cytotoxic T cells (CD8
+) 0.9 (± 0.6) 1.9 (± 0.6) 0.9 (± 0.4)
Neutrophils (CD16
+) 1.1 (± 0.7) 0.9 (± 1.5) 0.4 (± 0.7)
Macrophages (CD14
+) 1.7 (± 0.9) 1.3 (± 0.7) 0.9 (± 1.6)
Results are expressed as mean with standard deviation in brackets.
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tion of mediators.
The proportion of NK cells was significantly increased
in induced sputum in COPD subjects compared to smo-









predominate and are thought to play an immunoregula-
tory role [20]. In the COPD subjects we also show a sig-
nificantly increased proportion of the CD56
brightCD16
-
NK cells compared to smokers and HNS, suggesting a
possible regulatory role for these cells in the inflamma-
tory environment of the COPD lung.
The overall proportion of NKT-like cells was
increased in COPD subjects. The proportion of these
cells that expressed CD8 was significantly increased with
a corresponding decrease in those expressing CD4. The
double negative CD4
-CD8
- NKT cells were not different
between the groups. These CD8
+ NKT cells are known
to produce predominantly Th1-type cytokines [21-24],
which could influence the cytokine milieu within the
lung to one which is pro-inflammatory. Interestingly, no
difference in cytotoxic ability of the three NKT-like sub-
sets has been reported to date.
As well as showing an increased number of CD8
+
T lymphocytes, NK cells and NKT-like cells, we have
also shown that a significantly higher proportion of all
these cell types express both intracellular perforin and
granzyme B in COPD subjects compared to the other
two groups. Perforin is an important mediator of gran-
zyme B effector function in that it facilitates granzyme B
access to the target cell. Hence the presence of both
mediators is crucial for cell killing and our findings
highlight the potential importance of these killer cells in
the pathogenesis of COPD. Release of perforin and
granzyme B by CD8
+ T lymphocytes is hypothesised to
be an important mechanism in the development of
COPD [25].
The increased proportion of all cell types expressing
both mediators in COPD subjects leads one to hypothe-
sise that these cells are therefore more cytotoxic and
thus able to cause some of the damage seen in the
COPD lung. To confirm this hypothesis CD56
+ cell
cytotoxicity was measured using the LDH-release assay.
Here we show, for the first time, that CD56
+ cells have
greater specific lysis in COPD subjects than HNS and
smokers. However, biological lytic activity depends on
both the number of cells and specific lysis of each cell.
The product of the numbers and specific lysis is greater
in COPD subjects than HNS and smokers and is nega-
tively correlated with FEV1 in COPD subjects.
Both the increased proportion and cytotoxicity of NK
(CD56
+CD3
-) and NKT-like (CD56
+CD3
+) cells present
in the induced sputum of smokers with COPD is con-
trary to what was observed in the peripheral blood of
the same group [12]. This raises the possibility that the
cells are being selectively recruited to the lung. The
increased proportion of cells expressing CXCR3 and
VLA-4 support this hypothesis. Previously it has been
reported that the number of CXCR3
+ cells in the epithe-
lium and submucosa of COPD subjects are increased
Figure 4 Cytotoxic activity of CD56
+ cells (Panel A), biological
lytic activity (Panel B) and correlation of cytotoxic activity of
CD56
+ cells and lung function in COPD subjects (Panel C).
Immunomagnetically separated CD56
+ cells were significantly more
cytotoxic in COPD subjects than in HNS (***: p < 0.001) and
smokers (**: p < 0.01) and were inversely correlated with FEV1.
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increased in sputum from COPD subjects [27].
The present study has some limitations that deserve
comment. Firstly, seven patients received inhaled corti-
costeroids. For this reason, the results obtained in
patients receiving or not receiving inhaled cortico-
steroids were compared, and no significant differences
were found. Secondly, results generated from induced
sputum will reflect changes in the upper airways but
will not necessarily reflect lower airway changes or dif-
ferences within bronchial tissue. However, it is a conve-
nient and non-invasive research tool and differences
found in induced sputum need to be pursued [28,29]. It
would be important to follow up our findings by investi-
gating bronchoalveolar lavage and bronchial biopsies in
these groups of patients.
Of note is that the COPD subjects included current
and ex-smokers and that there was no difference in
terms of NK and NKT-like cell numbers or cytotoxi-
city between the two groups. A number of authors
have suggested that the airway inflammatory process
persists in ex-smokers with COPD [8,9,30]. Indeed, a
pooled analysis study demonstrated that there is no
significant difference in the inflammatory cell types
and markers between smokers and ex-smokers with
established COPD [31]. Alternatively, it could be that
the changes we have described are a consequence of
airway damage and therefore reflect previous smoking
induced damage of the airways. It is not possible with
our current data to determine whether these changes
are a consequence or part of the mechanism of airway
limitation.
In accordance with others [11,15,32,33] we have
shown that sputum cells treated with DTT are suitable
for flow cytometric analysis of both extracellular mar-
kers and intracellular proteins in lymphocytes. We have
also shown that DTT-treated cells are suitable for use
with a cytotoxicity assay.
Conclusion
In summary, we have shown an increased proportion of
three types of cytotoxic cells, namely CD8
+ T lympho-
cytes, NK and NKT-like cells, in the induced sputum of
COPD subjects and have demonstrated for the first time
that NK and NKT cells are significantly more cytotoxic
in COPD subjects than smokers and HNS. This comple-
ments our previous finding of reduced numbers and
cytotoxicity of these cells in the periphery. These cells
may play a part in the pathogenesis of disease or may
be a consequence of the underlying lung pathology.
Further studies are needed to explore possible mechan-
isms by which CD8
+ T lymphocytes, NK and NKT-like
cells may contibute to disease pathogenesis.
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